Similar to adults, treatment with tralokinumab for 1 year among adolescents with AD did not significantly affect laboratory parameters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results